Table 5.
Descriptive characteristics of patients with thromboembolic events.
| Study | Patients (n = 9) | Sex | Age | ACHD Type | NOAC * | Thromboembolic Event | Indication | CHA2DS2-VASc | HAS -BLED | Risk Factors and Comorbidities |
|---|---|---|---|---|---|---|---|---|---|---|
| Georgekutty [30] | 1 | M | 21 | Fontan | Dabigatran 110 mg b.i.d | Deep Vein Thrombosis | Persistent Right-to-Left Shunt | 1 | 0 | Protein-losing enteropathy |
| Yang [28] | 2 | M | 30 | Coronary atriovenous fistula | Dabigatran | Deep Vein Thrombosis | Atrial Arrhythmias | 3 | 2 | Severe Tricuspid Regurgitation |
| Yang [28] | 3 | M | 42 | Fontan | Apixaban | Pulmonary Embolism | Atrial Arrhythmias | 0 | 3 | - |
| Yang [28] | 4 | M | 25 | Fontan | Rivaroxaban | Intracardiac Thrombus | Atrial Arrhythmias | 2 | 1 | - |
| Yang [28] | 5 | M | 44 | Tetralogy Fallot | Apixaban | Pulmonary Embolism | Atrial Arrhythmias | 1 | 1 | - |
| Yang [28] | 6 | M | 23 | Fontan | Apixaban | Ischemic Stroke | Atrial Arrhythmias | 1 | 0 | - |
| Yang [28] | 7 | F | 25 | Transposition of Great Arteries | Apixaban | Intracardiac Thrombus | Atrial Arrhythmias | 4 | 0 | Severe Tricuspid Regurgitation |
| Pujol [29] | 8 | M | 51 | VSD (corrected) | Dabigatran 150 mg b.i.d | Stroke | Primary Thromboprophylaxis | 3 | 3 | Stroke, TIA, Liver Disease, Arterial Hypertension |
| Pujol [29] | 9 | M | 50 | Aortic Aneurysm | Rivaroxaban 20 mg q.d | Deep Vein Thrombosis | Primary Thromboprophylaxis | 1 | 1 | Arterial Hypertension |
Abbreviations: VSD: ventricular septal defect; TR: tricuspid valve regurgitation; TIA: Transient ischemic attack; b.i.d: twice a day; q.d: once a day. * NOAC dose indicated where reported.